Fate Therapeutics Inc
NASDAQ:FATE
EV/EBIT
Enterprise Value to EBIT
Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.
Market Cap | EV/EBIT | ||||
---|---|---|---|---|---|
US |
Fate Therapeutics Inc
NASDAQ:FATE
|
472.2m USD | -0.8 | ||
US |
Abbvie Inc
NYSE:ABBV
|
284.8B USD | 19.6 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
165.5B USD | 30.6 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.8B USD | 25.9 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
107.7B USD | 25 | ||
AU |
CSL Ltd
ASX:CSL
|
135.2B AUD | 27.1 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
84.2B USD | 9.2 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
48.1B USD | -7.8 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -55.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32.8B USD | 17.9 | ||
KR |
Celltrion Inc
KRX:068270
|
39.5T KRW | 62.2 |
EV/EBIT Forward Multiples
Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.